Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EADO 2018 /
NRAS mutant melanoma: Targeted therapy, are we there yet?

6th - 9th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.18
Views: 995

Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany

Prof Prof Dirk Schadendorf speaks with ecancer at the EADO 2018 congress in Barcelona about targeted therapy in NRAS mutant melanoma.

Prof Schadendorf explains that while BRAF mutations are favourable to treatment the NRAS mutation has proven harder to treat, with the NEMO study showing monotherapy not to be favourable.

He explains that for patients with a metastatic disease such as isolated systemic metastasis similar results or better can be achieved through surgery.

He details that there is promise from a study comparing nivolumab against chemotherapy DTIC with the use of nivolumab looking beneficial.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation